市场调查报告书
商品编码
1450839
创伤性脑损伤诊断设备市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围:按技术、设备类型、最终用户和地理位置Traumatic Brain Injury Diagnostics Equipment Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technique, Device Type, End User, and Geography |
创伤性脑损伤诊断设备市场规模预计将从2022年的31.57亿美元增长到2030年的78.72亿美元。对先进诊断设备的加速需求以及对TBI患者快速有效的诊断等因素推动了创伤性脑损伤诊断设备市场成长。然而,造影剂/造影剂的不利影响阻碍了市场的成长。
对先进诊断设备的需求加速推动创伤性脑损伤诊断设备市场的成长
根据医学研究委员会 2022 年报告,全球每年有 1,000 万人遭受创伤性脑损伤 (TBI)。同样,Headway 2024 报告显示,英国的后天性脑损伤 (ABI) 正在上升; 2019年至2020年,英国共有356,699例因ABI入院登记。其中,男性因头部受伤入院的人数是女性的1.5倍。根据经济学人智库的报告,TBI 每年对全球造成的医疗负担估计约 4,000 亿美元。最常见的 ABI 形式是由事故或中风引起的 TBI。美国疾病管制与预防中心 (CDC) 的报告显示,美国每年估计有 170 万人因 TBI 就诊、住院和死亡,尤其是 75 岁及以上的成年人,因为他们跌倒的风险很高。由于步态和平衡问题。此外,道路交通事故是美国 TBI 相关死亡的主要原因,并且在 20-24 岁的成年人中发病率最高。因此,製造商正在开发创新产品来诊断 TBI。 2023 年 10 月,生物梅里埃宣布「VIDAS TBI (GFAP, UCH-L1)」获得欧洲一致性 (CE) 标誌,旨在改善对轻度创伤性脑损伤 (mTBI) 患者的评估。 VIDAS TBI (GFAP, UCH-L1) test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1)-the two brain biomarkers released into the bloodstream starting from the first hour following a brain受伤.这是一项易于解释的测试,提供受伤后长达 12 小时的测试窗口,这有助于缩短急诊室的总检查时间。该产品将于 2023 年在部分欧洲、北非和南美市场上市;计划于 2024 年或 2025 年在全球推出。
用于诊断 TBI 患者的便携式非侵入性监测设备的出现是创伤性脑损伤诊断设备市场的未来趋势
监测组织代谢的新非侵入性方法可以帮助改善脑震盪、中风和 TBI 等脑部疾病的诊断和监测,从而使患者能够更快地康復。根据 BrainScope 公司白皮书,TBI 的后果导致医疗负担成本增加,每年达 765 亿美元。根据白色报告中揭露的研究结果,在较便宜的护理环境(例如急诊室和社区环境(包括紧急护理中心))中安装「BrainScope One」可能会导致医疗成本显着降低高达 32.2%纸。 BrainScope One 有助于消除不必要的 CT 扫描,从而降低 TBI 的医疗费用。
此外,来自密西根大学的一组研究人员开发了一种经济高效、便携式、非侵入性的工具——细胞色素 C 氧化酶超连续红外光谱 (SCISCCO) 系统——来检测神经元功能障碍。该工具用途极为广泛,具有多种用途,从作为筛检脑震盪患者的新设备到在重症监护病房中使用,再到测量患者器官对治疗的反应。
同样,伯明翰大学2024年报告显示,伯明翰大学的研究人员设计并开发了眼睛安全设备(EyeD)-一种检测TBI的新型诊断设备。它基于拉曼光谱,这是一种使用智慧型手机相机同时进行眼底成像和光谱分析的光学技术。 EyeD 从视网膜和视神经收集的拉曼光谱有助于使用人工神经网路演算法「SKiNET」作为决策支援工具来分析 TBI 特异性生化变化的存在。 EyeD快速、准确、非侵入性,不会造成额外的不适,并能立即提供有关创伤严重程度的信息,因此非常适合在现场使用——在不幸事件的路边或运动场上-评估TBI。
创伤性脑损伤诊断设备市场依技术分为非侵入性、侵入性和组合技术。侵入性细分市场在 2022 年占据最大的市场份额。非侵入性细分市场预计在预测期内CAGR最高,达到 12.8%。
创伤性脑损伤诊断设备市场依设备类型分为影像设备和监测设备。成像设备细分市场在 2022 年占据更大的市场份额,预计在预测期内复合CAGR将达到 11.8%。
依最终用户划分,创伤性脑损伤诊断设备市场分为医院和诊所、诊断中心等。医院和诊所细分市场在 2022 年占据最大的市场份额,预计在预测期内复合CAGR为 12.0%。
根据地理位置,创伤性脑损伤诊断设备市场分为北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美占据全球最大的脑外伤诊断设备市场。预计亚太地区 2022 年至 2030 年CAGR最高。在北美,美国占据脑外伤诊断设备市场最大的市场份额。美国疾病管制与预防中心 (CDC) 的报告显示,美国每年估计有 250 万人患有 TBI。根据 KNAPP & ROBERTS 报告,光是在美国,每 6 名美国人中就有 1 人患有与 TBI 相关的残疾,约占 10%。 530万。随着 TBI 盛行率的上升,其经济损失达 765 亿美元。 765亿美元中,115亿美元为直接医疗费用,近650亿美元为间接费用。 TBI的主要原因包括跌倒(45%)、机车碰撞(14.3%)、攻击(10.7%)和不明原因(19.0%)。
竞争格局及重点企业:
GE HealthCare Technologies Inc、Elekta AB、Integra LifeSciences Holdings Corp、Natus Medical Inc、Raumedic AG、BrainScope Co Inc、Luciole Medical AG、Soterix Medical Inc、Medtronic Plc、Vivonics Inc、NanoDx Inc、Compumedics Ltd、Sense Diagnostics Inc、NeuraSignal Inc、NeuraSignal Inc , 和Neurovigil Inc 是创伤性脑损伤诊断设备市场报告中的知名公司。这些公司专注于新技术、升级现有产品和地理扩张,以满足全球不断增长的消费者需求。
Sense Neuro Diagnostics 宣布获准进行出血检测临床试验。 FDA 神经外科、神经介入和神经诊断设备部门批准的这项新试验于 2023 年 6 月开始,包括来自美国、加拿大和印度 30 个地点的多达 300 名患者。这种非侵入性技术有可能在 2.5 秒内收集 360 个资料点,以检测脑出血或中风类型,从而帮助医生、急诊人员、神经 ICU 团队和军事野战医院评估和监测 TBI 做出快速反应。因此,由于美国公司推出创新产品以改善 TBI 患者的诊断结果,创伤性脑损伤诊断设备市场规模可能会激增。
註 - 将为以下提到的地区/国家提供类似的分析
The traumatic brain injury diagnostic equipment market size is expected to grow from US$ 3.157 billion in 2022 to US$ 7.872 billion by 2030. Factors such as the accelerated demand for advanced diagnostic equipment and quick and effective diagnosis for TBI patients propel the traumatic brain injury diagnostics equipment market growth. However, the adverse effects of contrast medium/agent impede the growth of the market.
Accelerated Demand for Advanced Diagnostic Equipment Drives Traumatic Brain Injury Diagnostics Equipment Market Growth
According to the Medical Research Council 2022 report, 10 million people across the world sustain traumatic brain injury (TBI) annually. Likewise, the Headway 2024 report revealed that acquired brain injury (ABI) is rising in the UK; a total of 356,699 hospital admissions were registered due to ABI in the UK from 2019 to 2020. Among these, the male population was 1.5 times higher than females admitted to hospitals for a head injury. As per The Economist Intelligence Unit report, the global healthcare burden of TBI is estimated to be around US$ 400 billion annually. The most common form of ABI is TBI due to an accident or stroke. The Centers for Disease Control and Prevention (CDC) report revealed that an estimated 1.7 million TBI-related emergency department visits, hospitalizations, and deaths occur annually in the US, especially among adults aged 75 years and older as they are at high risk of falling due to problems with gait and balance. Also, road accidents are the leading cause of TBI-related deaths in the US and are highest among adults aged 20-24 years. Therefore, manufacturers are developing innovative products to diagnose TBI. In October 2023, bioMerieux announced Conformite Europeenne (CE) marking for "VIDAS TBI (GFAP, UCH-L1)," a test intended to improve the assessment of patients suffering from mild traumatic brain injury (mTBI). VIDAS TBI (GFAP, UCH-L1) test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1)-the two brain biomarkers released into the bloodstream starting from the first hour following a brain injury. It is an easy-to-interpret test providing a test window of up to 12 hours after injury, which can help shorten total emergency department workup time. The product's commercial launch was in 2023 for selected European, North African, and South American markets; the global launch is planned in 2024 or 2025.
The emergence of Portable Noninvasive Monitoring Devices to Diagnose TBI Patients Acts as a Future Trend in Traumatic Brain Injury Diagnostics Equipment Market
New noninvasive methods for monitoring tissue metabolism can help improve the diagnosis and monitoring of brain conditions such as concussions, stroke, and TBI, owing to which patients can recover more quickly. The consequences of TBI resulted in increasing healthcare burden costs, accounting for US$ 76.5 billion annually, as per the BrainScope company white paper. The installation of "BrainScope One" in less expensive care settings-e.g., emergency department and community settings (including urgent care centers)-may result in a significant reduction of healthcare costs by up to 32.2%, as per the findings revealed in the white paper. BrainScope One aids in eliminating unnecessary CT scans, thereby reducing healthcare costs for TBI.
Further, a team of researchers from the University of Michigan developed a cost-effective, portable, noninvasive tool-Super-Continuum Infrared Spectroscopy of Cytochrome C-Oxidase (SCISCCO) system-to detect neuronal dysfunction. This tool is extremely versatile, having a range of uses from serving as a new device for screening concussion patients to use in the intensive care unit and gauging patients' organ response to treatment.
Likewise, the University of Birmingham 2024 report revealed that researchers from the University of Birmingham have designed and developed the eye-safe device (EyeD)-a novel diagnostic device to detect TBI. It is based on Raman spectroscopy, an optical technique performed simultaneously on fundus imaging and spectroscopic analysis using a smartphone camera. The Raman spectra collected by EyeD from the retina and optic nerves help in analyzing the presence of TBI-specific biochemical changes using the artificial neural network algorithm "SKiNET" as a decision support tool. EyeD is quick, accurate, and noninvasive, causes no additional discomfort, and provides information on the severity of the trauma instantly, owing to which it is highly suitable while using on-site-at the roadside of the unfortunate event or on the sports pitch-to assess TBI.
The traumatic brain injury diagnostics equipment market is segmented by technique into noninvasive, invasive, and combination techniques. The invasive segment held the largest market share in 2022. The noninvasive segment is anticipated to register the highest CAGR of 12.8% during the forecast period .
The traumatic brain injury diagnostics equipment market, by device type, is bifurcated into imaging devices and monitoring devices. The imaging devices segment held a larger market share in 2022 and is anticipated to register a higher CAGR of 11.8% during the forecast period .
The traumatic brain injury diagnostics equipment market, by end user, is categorized into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment held the largest market share in 2022 and is anticipated to register a CAGR of 12.0% during the forecast period .
Based on geography, the traumatic brain injury diagnostic equipment market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America accounted for the largest global traumatic brain injury diagnostic equipment market share. Asia Pacific is expected to register the highest CAGR during 2022-2030. In North America, the US accounts for the largest market share of the traumatic brain injury diagnostic equipment market. The Centers for Disease Control and Prevention (CDC) report revealed that an estimated 2.5 million people suffer from TBI annually in the US. According to the KNAPP & ROBERTS report, 1 in every 6 Americans live with TBI-related disability in the US alone, accounting for approx. 5.3 million. With the rising prevalence of TBI, the economic cost accounts for US$ 76.5 billion. Among US$ 76.5 billion, US$ 11.5 billion accounts for direct medical costs and nearly US$ 65 billion for indirect costs. The leading causes of TBI include falls (45%), motor vehicle crashes (14.3%), assaults (10.7%), and unknown (19.0%).
Competitive Landscape and Key Companies:
GE HealthCare Technologies Inc, Elekta AB, Integra LifeSciences Holdings Corp, Natus Medical Inc, Raumedic AG, BrainScope Co Inc, Luciole Medical AG, Soterix Medical Inc, Medtronic Plc, Vivonics Inc, NanoDx Inc, Compumedics Ltd, Sense Diagnostics Inc, NeuraSignal Inc, and Neurovigil Inc are the prominent companies in the traumatic brain injury diagnostic equipment market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.
Sense Neuro Diagnostics announced clearance to conduct clinical trials for hemorrhage detection. The new trial approved by the FDA Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices began in June 2023, including up to 300 patients at 30 US, Canada, and Indian sites. This noninvasive technology has the potential to collect 360 data points within 2.5 seconds to detect brain hemorrhage or stroke type, thereby helping quick response by physicians, emergency department personnel, neuro ICU teams, and military field hospitals assessing and monitoring TBI. Therefore, the traumatic brain injury diagnostics equipment market size is likely to surge due to innovative product launches by US-based companies to improve outcomes of diagnosis of patients suffering from TBI.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies